Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Frequently Asked Questions What causes osteoporosis? No single cause for osteoporosis has been identified. However, certain factors – called risk factors – do seem to play a role in the […]

Risk Factors At least 1 in 3 women and 1 in 5 men will break a bone from osteoporosis. Did you know? Fractures from osteoporosis are more common than heart […]

New survey reveals Canadians are largely unaware about osteoporosis and the serious consequences it can have on their health TORONTO, ON (February 2, 2016) – Snow and ice can make walking […]

DIAGNOSIS The importance of a comprehensive fracture risk assessment Insist on Assessment Osteoporosis often goes undiagnosed until a bone fractures, and is therefore commonly referred to as “the silent thief”. […]

In 15 of the studies the mean baseline vitamin D level was over 50 nmol/l which is higher than values seen in a significant number of Canadian men and women […]

Vitamin D supplementation has recently been evaluated in Switzerland in a small 1 year randomized clinical trial by Bischoff-Ferrari and colleagues. This study compared the effects of two “high” doses […]

Denosumab (Prolia) has been shown to reduce the risk of fracture in postmenopausal women and men ≥50 years old with osteoporosis. It has also been approved for steroid induced bone […]

Osteoporosis Canada advises individuals on denosumab therapy to discuss their treatment with their physician prior to delaying therapy, stopping therapy or missing a scheduled dose.   Denosumab (Prolia) has been […]